abbott laboratories

In a report published Sunday, Goldman Sachs analyst David H. Roman upgraded the rating on Abbott Laboratories (NYSE: ABT) from Neutral to Buy and raised the price target on the company from $38.00 to $44.00. In the report, Goldman Sachs noted, "(1) Emerging markets growth is taking hold faster...

  MAKING THE VALUE PROPOSITION FOR STAR SCIENTIFIC Tobacco could kill one billion people this century -(Reuters) Part one: CigRx™, the over-the-counter nutraceutical that reduces the urge to smoke. My recent reports on Star Scientific have dealt largely with...

Morgan Stanley provided color on Abbott Laboratories (NYSE: ABT) after an FDA panel discussed the safety of some of its products. In a research report published today, Morgan Stanley states, "An FDA panel convened yesterday to discuss safety data from the ACCORD study of combination fenofibrate/...

According to Wedbush, Abbott Laboratories (NYSE: ABT) solid results gave no boost to the stock. Wedbush said that Abbott Labs beat Q1 expectations, guided Q2 and full year numbers in line, sustained strong growth for its largest product, validated its emerging markets growth model, and outlined an...

Morgan Stanley is out with its report today on Abbott Laboratories (NYSE: ABT), maintaining Overweight. In a note to clients, Morgan Stanley writes, "Our 12-month price target for ABT is $55. Our price target is based on 11x Base Case 2012e EPS of $5.06. This represents a blend of valuation...

J.P. Morgan is lowering its PT on Abbott Laboratories (NYSE: ABT) to $55 from $60.

Citigroup has lowered the price target on Abbott Laboratories (NYSE: ABT) from $52 to $48 and maintains its Hold rating.

The holiday season is here and, it brings a vast array of delicious products with it. From big dinners, to desserts galore, the holidays are typically a chance to attack the buffet at full-force. Odds are Santa won't be the only one packing on a few pounds after overdosing on milk and cookies. A...

Goldman Sachs decreases its price target on Abbott Laboratories (NYSE: ABT) from $58 to $54. In a note to clients, Goldman Sachs writes, "With our updated immunology market model, we are modestly reducing our Humira estimates by $100 mn in 2011 to $500 mn in 2015. We are also lowering our ABT 12-...

JP Morgan has issued a research report on Abbott Laboratories (NYSE: ABT) previewing the company's 3Q results. In the report, JP Morgan writes "For the quarter, our model calls for EPS of $1.04 (+13.0%), which is inline with consensus and at the midpoint of management's guidance range of $1.03-1.05...

Upgrades: Estacio Participacoes SA (SAO: ESTC3) upgraded from Equal to Overweight, price target remains at $25, 2010 EPS raised to $1.15 (from $1.12), 2011 raised to $1.32 (from $1.15). Downgrades: Adobe Systems (NASDAQ: ADBE) downgraded to Equal from Overweight, price target remains at $42....